

# Mariangela Cicarese

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1875867/publications.pdf>

Version: 2024-02-01

10  
papers

70  
citations

1684188

5  
h-index

1588992

8  
g-index

12  
all docs

12  
docs citations

12  
times ranked

229  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.   | 7.0 | 4         |
| 2  | Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies. <i>Breast Care</i> , 2020, 15, 30-37. | 1.4 | 0         |
| 3  | A multicenter phase II trial of nab-paclitaxel and capecitabine in HER2 negative and triple-negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?. <i>Breast Journal</i> , 2020, 26, 1857-1859.   | 1.0 | 0         |
| 4  | Pharmacotherapeutic options for patients with refractory breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 851-861.  | 1.8 | 3         |
| 5  | An update on first line therapies for metastatic breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 243-252.  | 1.8 | 8         |
| 6  | Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018, 38, 86-91.  | 2.2 | 27        |
| 7  | Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged $\geq 65$ years: new lessons for clinical practice from the EVA study. <i>Oncotarget</i> , 2018, 9, 31877-31887.  | 1.8 | 4         |
| 8  | Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 587-594. | 2.5 | 9         |
| 9  | Prognostic model for advanced breast carcinoma with luminal subtype and impact of hormonal maintenance: Implications for post-progression and conditional survival. <i>Breast</i> , 2016, 29, 24-30.   | 2.2 | 9         |
| 10 | A Delphi consensus and open debate on the role of first-line bevacizumab for HER2-negative metastatic breast cancer. <i>Future Oncology</i> , 2016, 12, 2589-2602.   | 2.4 | 6         |